Pluristem Therapeutics Inc. (NASDAQ:PSTI) has received a consensus rating of “Buy” from the six ratings firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $3.67.
PSTI has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 12th. B. Riley initiated coverage on shares of Pluristem Therapeutics in a research note on Tuesday, July 31st. They issued a “buy” rating and a $4.50 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $3.50 target price on shares of Pluristem Therapeutics in a research note on Friday, September 28th.
A hedge fund recently raised its stake in Pluristem Therapeutics stock. ARK Investment Management LLC lifted its holdings in shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 87.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,436,501 shares of the biotechnology company’s stock after buying an additional 669,077 shares during the period. ARK Investment Management LLC owned 1.30% of Pluristem Therapeutics worth $1,753,000 at the end of the most recent reporting period. Institutional investors own 3.54% of the company’s stock.
PSTI stock traded up $0.02 during trading on Monday, reaching $1.20. The stock had a trading volume of 203,625 shares, compared to its average volume of 281,309. Pluristem Therapeutics has a 1-year low of $1.13 and a 1-year high of $2.12. The firm has a market capitalization of $134.04 million, a P/E ratio of -4.80 and a beta of 0.32.
Pluristem Therapeutics (NASDAQ:PSTI) last issued its quarterly earnings data on Thursday, September 27th. The biotechnology company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). The firm had revenue of $0.05 million during the quarter. Research analysts predict that Pluristem Therapeutics will post -0.36 EPS for the current fiscal year.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Featured Story: What is dollar cost averaging (DCA)?
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.